News

La FDA approuve CorNeat EverPatch, le premier substitut tissulaire synthétique non dégradable pour la chirurgie ophtalmique

by

CorNeat EverPatch est sur le point de remplacer l’utilisation de tissus de donneurs et de tissus traités, couramment utilisés dans les chirurgies oculaires, présentant  un risque de transmission de maladies. Le Dr Gilad Litvin, médecin en chef et co-fondateur de CorNeat Vision, a déclaré : « Le matériau de greffe idéal doit être durable, stérile, immunologiquement inactif, esthétiquement acceptable et facilement … Read more

FDA Clears CorNeat EverPatch, World’s First Non-degradable, Synthetic Tissue Substitute for Ophthalmic Surgery

by

The CorNeat EverPatch is poised to displace the use of donor and processed tissue, commonly utilized in ocular surgeries but posing the risk of disease transmission. Dr. Gilad Litvin, CorNeat Vision’s Chief Medical Officer and Co-Founder stated: “The ideal graft material should be long-lasting, sterile, immunologically inactive, cosmetically acceptable, and readily available. The CorNeat EverPatch … Read more

FDA genehmigt CorNeat EverPatch, das weltweit erste nicht degradierbare synthetische Gewebeersatzmaterial für die Augenchirurgie

by

Der CorNeat EverPatch ist in der Lage, die Verwendung von Spender- und verarbeitetem Gewebe zu ersetzen, das üblicherweise bei Augenoperationen eingesetzt wird, aber das Risiko von Krankheitsübertragungen birgt. Dr. Gilad Litvin, Chief Medical Officer und Mitbegründer von CorNeat Vision, erklärte: „Das ideale Transplantatmaterial sollte langlebig, steril, immunologisch inaktiv, kosmetisch akzeptabel und leicht verfügbar sein. Genau … Read more

Indivior to Commence Trading on Nasdaq

by

Company to Ring Opening Bell June 14 to Bring Awareness to Addiction Treatment; Company Will Maintain Premium Listing on London Stock Exchange RICHMOND, Va., June 12, 2023 /PRNewswire/ — Indivior PLC (LSE: INDV), a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD) and serious mental illnesses, … Read more

Jelenew Teams Up with Olympic Medalist Marion Clignet Teams for an Inspiring Charity Ride to raise funds to build a gym for a local school dedicated to children with epilepsy #empowerwomen USA – English USA – English Deutschland – Deutsch USA – English

by

WILMINGTON, Del., June 12, 2023 /PRNewswire/ — Jelenew, a leading luxury women’s cycling brand, recently orchestrated a charity cyclosportive to uplift and advocate for individuals affected by epilepsy. This event took place on the third of June in the picturesque setting of Mauvezin, Gers, and aims to raise awareness and funds to build a gym … Read more

Jelenew Teams Up with Olympic Medalist Marion Clignet Teams for an Inspiring Charity Ride to raise funds to build a gym for a local school dedicated to children with epilepsy #empowerwomen

by

WILMINGTON, Del., June 12, 2023 /PRNewswire/ — Jelenew, a leading luxury women’s cycling brand, recently orchestrated a charity cyclosportive to uplift and advocate for individuals affected by epilepsy. This event took place on the third of June in the picturesque setting of Mauvezin, Gers, and aims to raise awareness and funds to build a gym … Read more

The American Heart Association Hosts “A Dinner Party with Heart” to Support Nation of Lifesavers™ Initiative

by

Celebrities, athletes, and influencers gathered on Saturday in Los Angeles for an evening of celebration and a show of support to join the Nation of Lifesavers™ initiative. Editor/producer note: News release includes quotes and links to images. LOS ANGELES, June 11, 2023 /PRNewswire/ — The American Heart Association, the world’s leading voluntary organization dedicated to building … Read more

Sanyou Milestones | Super Trillion Common Light Chain Antibody Discovery Platform Launched

by

SHANGHAI, June 11, 2023 /PRNewswire/ — On June 12th, 2023 local time, Sanyou Biopharmaceuticals Co., Ltd. officially announced the launch of “Sanyou Super Trillion Common Light Chain Antibody Discovery Platform” (the “platform”). As one of the nine trillion antibody discovery platforms of Sanyou, the platform features a library capacity of up to 1.12E+12 CFU. For … Read more

Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases

by

– Proceeds to support the development of Eccogene’s clinical-stage metabolic pipeline including ECC5004, a small molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and ECC4703, a THRβ full agonist for NASH and lipid disorders BOSTON and SHANGHAI, June 11, 2023 /PRNewswire/ — Eccogene Inc., a clinical-stage biotechnology company developing innovative therapeutic solutions for metabolic … Read more

Innovent Announces Phase 1 Clinical Data of IBI322 (CD47/PD-L1 Bispecific Antibody) in the Treatment of Anti-PD-(L)1-resistant Classic Hodgkin Lymphoma Patients at the EHA 2023 Annual Meeting APAC – English USA – English

by

ROCKVILLE, Md. and SUZHOU, China, June 11, 2023 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other 1major diseases, announced that Phase 1 clinical data of the globally first anti-CD47/PD-L1 bispecific antibody IBI322 for … Read more